PL1699462T3 - Połączenie [6R]-metylenotetrahydrofolanu z antyfolanami ukierunkowanymi na wiele celów do zmniejszania ich toksyczności podczas leczenia raka - Google Patents

Połączenie [6R]-metylenotetrahydrofolanu z antyfolanami ukierunkowanymi na wiele celów do zmniejszania ich toksyczności podczas leczenia raka

Info

Publication number
PL1699462T3
PL1699462T3 PL04809128T PL04809128T PL1699462T3 PL 1699462 T3 PL1699462 T3 PL 1699462T3 PL 04809128 T PL04809128 T PL 04809128T PL 04809128 T PL04809128 T PL 04809128T PL 1699462 T3 PL1699462 T3 PL 1699462T3
Authority
PL
Poland
Prior art keywords
tetrahydrofolate
methylenetetrahydrofolate
toxicity
combination
reduce
Prior art date
Application number
PL04809128T
Other languages
English (en)
Inventor
Bengt Gustavsson
Göran Carlsson
Original Assignee
Isofol Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isofol Medical Ab filed Critical Isofol Medical Ab
Publication of PL1699462T3 publication Critical patent/PL1699462T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
PL04809128T 2003-12-22 2004-12-22 Połączenie [6R]-metylenotetrahydrofolanu z antyfolanami ukierunkowanymi na wiele celów do zmniejszania ich toksyczności podczas leczenia raka PL1699462T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0303526A SE0303526D0 (sv) 2003-12-22 2003-12-22 Chemotherapeutic agents
EP04809128A EP1699462B1 (en) 2003-12-22 2004-12-22 Combination of [6R]-methylenetetrahydrofolate with multi-targeting antifolates to reduce their toxicity while treating cancer
PCT/SE2004/001955 WO2005060973A1 (en) 2003-12-22 2004-12-22 Reduction of toxicity of multi-targeting antifolates

Publications (1)

Publication Number Publication Date
PL1699462T3 true PL1699462T3 (pl) 2011-04-29

Family

ID=30768841

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04809128T PL1699462T3 (pl) 2003-12-22 2004-12-22 Połączenie [6R]-metylenotetrahydrofolanu z antyfolanami ukierunkowanymi na wiele celów do zmniejszania ich toksyczności podczas leczenia raka

Country Status (14)

Country Link
US (3) US20070249613A1 (pl)
EP (1) EP1699462B1 (pl)
JP (2) JP5043441B2 (pl)
AT (1) ATE476996T1 (pl)
CA (1) CA2550298C (pl)
CY (1) CY1110859T1 (pl)
DE (1) DE602004028654D1 (pl)
DK (1) DK1699462T3 (pl)
ES (2) ES2349929T3 (pl)
PL (1) PL1699462T3 (pl)
PT (1) PT1699462E (pl)
SE (1) SE0303526D0 (pl)
SI (1) SI1699462T1 (pl)
WO (1) WO2005060973A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303526D0 (sv) 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
EP2617422A1 (en) 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2617421A1 (en) 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
KR101673979B1 (ko) * 2012-04-13 2016-11-08 리안윤강 진강 해신 파머수티컬 코. 엘티디. 화합물 jk12a 및 그 제조
NL2019147B1 (en) 2017-06-29 2019-01-14 D O R C Dutch Ophthalmic Res Center International B V A foot pedal control unit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
CA2082811C (en) * 1990-05-11 2004-11-16 Colin P. Spears 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6921667B2 (en) * 2003-03-07 2005-07-26 Prometheus Laboratories, Inc. Methods for direct detection of individual methotrexate metabolites
SE0303526D0 (sv) 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents

Also Published As

Publication number Publication date
WO2005060973A1 (en) 2005-07-07
US20100311762A1 (en) 2010-12-09
JP2007515482A (ja) 2007-06-14
SE0303526D0 (sv) 2003-12-22
DE602004028654D1 (de) 2010-09-23
SI1699462T1 (sl) 2010-12-31
JP5043441B2 (ja) 2012-10-10
EP1699462B1 (en) 2010-08-11
US20150328218A1 (en) 2015-11-19
EP1699462A1 (en) 2006-09-13
CY1110859T1 (el) 2015-06-10
PT1699462E (pt) 2010-11-05
DK1699462T3 (da) 2010-11-08
ES2349930T3 (es) 2011-01-13
CA2550298A1 (en) 2005-07-07
US20070249613A1 (en) 2007-10-25
ATE476996T1 (de) 2010-08-15
JP2012087130A (ja) 2012-05-10
CA2550298C (en) 2013-05-28
US9138435B2 (en) 2015-09-22
US9585888B2 (en) 2017-03-07
ES2349929T3 (es) 2011-01-13

Similar Documents

Publication Publication Date Title
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
WO2005105094A3 (en) Cancer treatment method
HK1096392A1 (en) Substituted heterocycles
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
WO2005018555A3 (en) Lipid-modified immune response modifiers
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
MX2009002995A (es) Derivados de pirazolo-[1,5-a]-pirimidina y su uso terapeutico.
HK1071310A1 (en) Combination therapy for the treatment of cancer
CY1110859T1 (el) Συνδυασμος [6r]-meθyλenotetpayδpοφολikoy με πολυ-στοχοθετικα αντιφολικα για να μειωνεται τοξικοτητα αυτων ενω θεραπευεται καρκινος
YU64602A (sh) Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2005025501A3 (en) Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine
WO2005000204A3 (en) Pancreatic cancer treatment
PL1718651T3 (pl) Pochodne 7H-pirolopirymidyny
WO2005092385A3 (en) Combination therapy of azd2171 and a taxane
HK1086493A1 (en) Treatment of proliferative diseases with epothilone derivatives and radiation
IL174365A (en) Bravatoxin Polyether Compounds, Pharmaceutical Formulations and the Use of Drug Preparation
WO2007043094A3 (en) 6-vinyl pyrimidine and pyrimidinone derivatives and the use thereof
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases
MXPA04005901A (es) Composiciones a base de taxano y metodos de uso.